Results 281 to 290 of about 38,272 (314)

Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure.

Circulation
BACKGROUND Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of cardiovascular death or worsening heart failure (HF) in outpatients with HF. Data are limited regarding initiation in patients hospitalized for HF.
David D. Berg, Siddharth M. Patel, P. Haller, Abby L. Cange, M. Palazzolo, A. Bellavia, J. Kuder, A. Desai, S. Inzucchi, J. McMurray, E. O'Meara, Subodh Verma, J. Bělohlávek, Jarosław Drożdż, B. Merkely, Modele O Ogunniyi, T. Drasnar, Joseph L. Izzo, Balazs Sarman, John Mcginty, Krishnan Ramanathan, Angel J. Mulkay, Andrzej Przybylski, Christian T. Ruff, Michelle L. O'Donoghue, S. Murphy, M. Sabatine, S. Wiviott   +27 more
semanticscholar   +1 more source

Effect of dapagliflozin on the no-reflow phenomenon in patients with acute myocardial infarction and type II diabetes mellitus

Acta Cardiologica
Objective This study aimed to assess the effect of dapagliflozin on the no-reflow phenomenon in patients with type II diabetes mellitus (T2DM) and acute myocardial infarction (AMI) who underwent percutaneous coronary intervention (PCI).
A. Quisi, Nur Selin Nacar Quisi, Gokhan Alici, İdil Donma, A. Yıldırım, Ö. Genç   +5 more
semanticscholar   +1 more source

Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction: The DEFENDER Randomized Clinical Trial.

Journal of the American Medical Association (JAMA)
Importance Sodium-glucose cotransporter 2 (SGLT-2) inhibitors improve outcomes in patients with type 2 diabetes, heart failure, and chronic kidney disease, but their effect on outcomes of critically ill patients with organ failure is unknown ...
Caio A M Tavares, L. Azevedo, Á. Réa-Neto, Niklas S. Campos, C. P. Amêndola, A. C. Kozesinski-Nakatani, P. G. David-João, S. Lobo, Thiago C Filiponi, Guacyra Almeida, R. R. Bergo, Mário R R Guimarães-Júnior, Rodrigo Figueiredo, Joan R Castro, Clewer J. Schuler, G. Westphal, Ana C R Carioca, Frederico Monfradini, J. Nieri, Flavia M O Neves, Jaqueline A Paulo, C. S. Albuquerque, M. C. R. Silva, Mikhail N. Kosiborod, A. J. Pereira, L. Damiani, T. Corrêa, A. Serpa-Neto, O. Berwanger, F. Zampieri   +29 more
semanticscholar   +1 more source

Dapagliflozin

Reactions Weekly, 2021
  +5 more sources

Dapagliflozin

Reactions Weekly, 2019
  +7 more sources

Dapagliflozin and Right Ventricular-Pulmonary Vascular Interaction in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of a Randomized Clinical Trial.

JAMA cardiology
Importance Increases in pulmonary capillary wedge pressure (PCWP) during exercise reduce pulmonary artery (PA) compliance, increase pulsatile right ventricular (RV) afterload, and impair RV-PA coupling in patients with heart failure with preserved ...
Y. Reddy, Rickey E. Carter, H. Sorimachi, M. Omar, D. Popović, A. Alogna, M. Jensen, B. Borlaug   +7 more
semanticscholar   +1 more source

Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial

Circulation
BACKGROUND: Systemic arterial compliance and venous capacitance are typically impaired in patients with heart failure with preserved ejection fraction (HFpEF), contributing to hemodynamic congestion with stress.
A. Tada, D. Burkhoff, J. Naser, T. Harada, B. Pourmussa, Y. N. Reddy, Michael D. Jensen, R. Carter, R. Demmer, Jeffrey M. Testani, Julio A. Chirinos, B. Borlaug   +11 more
semanticscholar   +1 more source

Dapagliflozin

Reactions Weekly, 2022
  +6 more sources

Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction

Circulation: Heart Failure
BACKGROUND: Mechanisms of benefit with SGLT2is (sodium-glucose cotransporter-2 inhibitors) in heart failure (HF) remain incompletely characterized. Dapagliflozin alters ketone and fatty acid metabolism in HF with reduced ejection fraction though similar ...
Senthil Selvaraj, Shachi Patel, Andrew J. Sauer, R. McGarrah, Philip G. Jones, L. Kwee, Sheryl L. Windsor, Olga R. Ilkayeva, Michael J. Muehlbauer, Christopher B. Newgard, B. Borlaug, D. Kitzman, Sanjiv J. Shah, K. Margulies, Mansoor Husain, S. Inzucchi, Darren K. McGuire, D. Lanfear, A. Javaheri, Guillermo Umpierrez, Robert J. Mentz, Kavita Sharma, Mikhail N. Kosiborod, Svati H. Shah   +23 more
semanticscholar   +1 more source

Dapagliflozin

Reactions Weekly, 2018
  +6 more sources